Chimeric Antigen Receptors to CD276 (B7-H3) for Treatment of Cancer

Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains. When CARs are expressed in T-cells, the T-cells become cytotoxic towards cells expressing the proteins that the CAR recognizes. By developing a CAR that is specific for a cell surface protein that is selectively expressed on diseased cells, it is possible to selectively target those cells for destruction, thereby treating the disease.

Solid tumors are typically treated with a non-specific approach of surgical resection, followed by chemotherapy or radiation therapy. Unfortunately, such an approach is traumatic for the patient, and leads to numerous side-effects. This suggests that a more specific approach to treating solid tumors is needed. CD276 (B7-H3) is a tumor-associated antigen that is expressed on several solid tumors, making it a promising therapeutic target. This technology concerns the generation of three high-affinity CARs (CD276.1, CD276.6 and CD276.17) that target CD276. These CARs can potentially be used in the treatment of cancers associated with CD276 expression.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of diseases associated with increased or preferential expression of CD276.
  • Specific diseases include neuroblastoma, Ewing’s sarcoma, rhabdomyosarcoma, and prostate, ovarian, colorectal, and lung cancers.
  • High affinity of the CARs increases the likelihood of successful targeting.
  • Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients.

Development Stage:
  • Early-stage
  • In vitro data available

Related Invention(s):


Rimas Orentas (NCI)  ➽ more inventions...

Crystal Mackall (NCI)  ➽ more inventions...

Dimiter Dimitrov (NCI)  ➽ more inventions...

Zhongyu Zhu (NCI)  ➽ more inventions...

Brad St. Croix (NCI)  ➽ more inventions...

Saurabh Saha

Intellectual Property:
U.S. Pat: 9,790,282 issued 2017-10-17
PCT Application No. PCT/US2014/031543
US Application No. 14/779,586
US Application No. 15/699,419

Licensing Contact:
Rose Freel, Ph.D.
Phone: 301-624-1257

OTT Reference No: E-104-2013-0
Updated: Aug 22, 2018